You are viewing the site in preview mode

Skip to main content

Advertisement

Figure 2 | Radiation Oncology

Figure 2

From: Short course radiotherapy with simultaneous integrated boost for stage I-II breast cancer, early toxicities of a randomized clinical trial

Figure 2

DVHs of the ipsilateral lung for patients who showed consistent DLco-decrease of >10%. The individual DVHs for the patients who had G1 or higher lung toxicity based on DLco, which proved consistent over time, are shown compared to the average DVH for TT and CR. The dose is formulated in 2 Gy equivalent dose (EQ2) with an alpha/beta of 3 Gy.

Back to article page